Industry

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

– IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more “Good On” time with fewer doses BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral … [Read more…]

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup … [Read more…]

Omnicell to Present at the 2022 Wells Fargo Healthcare Conference

SANTA CLARA, Calif.–(BUSINESS WIRE)–Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference: Scott Seidelmann, Omnicell Executive Vice President, Chief Commercial Officer, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 1:55p.m. Eastern … [Read more…]

MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MUNICH–(BUSINESS WIRE)–MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His … [Read more…]

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to fund development from preclinical stage through Phase 1 over three-year period A lower-dose, freeze-dried, pandemic influenza … [Read more…]

CommonWell To Apply to Become One of TEFCA’s First Qualified Health Information Networks

BOSTON–(BUSINESS WIRE)–#InteropDoneRight–The CommonWell Health Alliance® today announced its intention to apply to become one of the first Qualified Health Information Networks (QHIN) as part of the Trusted Exchange Framework and Common Agreement (TEFCA). CommonWell will submit its application with the first set of submissions. This move follows The Sequoia Project, the Recognized Coordinating Entity for … [Read more…]

Mayo Clinic and PN Medical Publish Study that Shows How to Reduce Stress and Anxiety

An 18% reduction in stress was one of the most significant outcomes. ORLANDO, Fla.–(BUSINESS WIRE)–Mayo Clinic released the results of a clinical trial demonstrating the positive outcomes of a Comprehensive Wellness Program for reducing stress and improving resilience among healthcare professionals. Integral to the study was the participants’ use of BREATHER FIT®, one of PN … [Read more…]

High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend

On International Overdose Awareness Day, community encouraged to learn about additional treatment options to help save lives LOUISVILLE, Ky.–(BUSINESS WIRE)–Today is International Overdose Awareness Day, and ZIMHI™ (naloxone HCL injection), a higher-dose naloxone product approved for use in the treatment of opioid overdose, is helping bring attention to the growing opioid epidemic in the United … [Read more…]

Worldwide Hereditary Angioedema Industry to 2030 – Players Include CSL Behring, Takeda Pharmaceutical, Pharming and Ionis Pharmaceuticals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hereditary Angioedema Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. … [Read more…]

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccines Pfizer-BioNTech Omicron BA.4/BA.5 Bivalent Vaccine combines 15-µg of mRNA encoding the wild-type spike protein found in the Original Pfizer-BioNTech COVID-19 Vaccine and 15-µg of mRNA encoding the spike protein of the OmicronBA.4/BA.5 subvariants Pfizer-BioNTech Omicron BA.4/BA.5 COVID-19 Bivalent Vaccine available to ship immediately … [Read more…]